COMMODORE CAPITAL LP
Q3 2026 Form 13-F
NEW YORK, NEW YORK
CIK 0001831942
· CRD 304370
· SEC-registered investment adviser
$1.3B Reported Value Total
COMMODORE CAPITAL reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $2,369,313,969, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
1 fund
· $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-03-31
Reported value
$1.3B
Quarter over quarter
-6.4%
Holdings
37
Top-10 concentration
65.2%
Key People
Form ADV owners & control persons
Robert Egen Turrell Atkinson
MEMBER
Michael Jonathan Kramarz
LIMITED PARTNER
Ameya Vikas Bapat
CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, GENERAL COUNSEL
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $1.3B |
| Positions | 37 |
| Change in reported value | -23.1% |
| New positions | 11 |
| Exited positions | 7 |
| Position turnover | 40.9% |
| Top-10 concentration | 65.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
37 | $1.3B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
33 | $1.7B |
|
Q1 2026 13F
Filed May 15, 2026
|
36 | $1.7B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
33 | $1.5B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
37 | $2.0B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
33 | $1.4B |
|
Q1 2025 13F
Filed May 15, 2025
|
31 | $1.4B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
31 | $1.4B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
36 | $1.6B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
35 | $1.5B |
|
Q1 2024 13F
Filed May 15, 2024
|
39 | $1.5B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
32 | $1.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
30 | $855.5M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
26 | $889.8M |
|
Q1 2023 13F
Filed May 15, 2023
|
32 | $656.8M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
35 | $663.5M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
30 | $621.9M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
24 | $473.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
27 | $447.7M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
25 | $431.8M |
4 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RLAY RELAY THERAPEUTICS INC | $216.6M | 16.78% |
| 2 | ELVN ENLIVEN THERAPEUTICS INC | $150.1M | 11.63% |
| 3 | ALKS ALKERMES PLC | $116.5M | 9.03% |
| 4 | ANRO ALTO NEUROSCIENCE INC | $69.5M | 5.39% |
| 5 | SYRE SPYRE THERAPEUTICS INC | $62.3M | 4.83% |
| 6 | AMLX AMYLYX PHARMACEUTICALS INC | $58.2M | 4.51% |
| 7 | LBRX LB PHARMACEUTICALS INC | $49.2M | 3.81% |
| 8 | DMRA DAMORA THERAPEUTICS INC | $41.3M | 3.2% |
| 9 | COGT COGENT BIOSCIENCES INC | $40.5M | 3.14% |
| 10 | TYRA TYRA BIOSCIENCES INC | $37.7M | 2.92% |
| 11 | CLDX CELLDEX THERAPEUTICS INC NEW | $32.4M | 2.51% |
| 12 | PHVS PHARVARIS N V | $29.3M | 2.27% |
| 13 | SRZN SURROZEN INC | $28.5M | 2.21% |
| 14 | KRSA KORSANA BIOSCIENCES INC | $28.1M | 2.17% |
| 15 | SGMT SAGIMET BIOSCIENCES INC | $27.2M | 2.11% |
| 16 | DFTX DEFINIUM THERAPEUTICS INC | $26.6M | 2.06% |
| 17 | ADRX ADARX PHARMACEUTICALS INC | $25.1M | 1.95% |
| 18 | EDIT EDITAS MEDICINE INC | $22.8M | 1.77% |
| 19 | ENTX ENTERA BIO LTD | $21.4M | 1.66% |
| 20 | ATTO ATTOVIA THERAPEUTICS INC | $19.9M | 1.54% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.